Study analysis · Nature Genetics · 2003
Scientists found a third gene behind inherited high cholesterol—and it wasn't LDLR or APOB.
A tiny change in a gene called PCSK9 can cause very high cholesterol that runs in families.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study found that people with a certain cholesterol problem often have changes in a specific gene. It's like noticing that people with a disease often have a certain feature, but it doesn't prove the feature causes the disease. We can only say they are linked, not that one causes the other.
What’s the bottom line?
Scientists found that two tiny changes in a gene called PCSK9 can cause a severe inherited form of high cholesterol called autosomal dominant hypercholesterolemia. This gene makes a protein called NARC-1 that is active in the liver and helps control cholesterol.
How strong is this study?
We only have a short summary of the study, not all the details. That makes it hard to know if the study was done well, so we should be careful about trusting the results too much. More research is needed to confirm.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
0 / 100
- Randomizationrandomization unclear
- Blindingblinding unclear
- Control groupno control group
- Sample sizeno sample size reported
- Follow-upno follow-up reported
100 / 100
0 / 100
- P-valuesno p-values reported
- Effect sizeno effect size reported
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 520 / 100
Probability of being correct
Researchers compare people who have a condition (cases) with similar people who do not (controls), looking back in time for differences in exposure. Useful but more prone to bias.
This design cannot establish causation — the findings describe an association, not a cause. Case-control design cannot establish causation due to lack of randomization, potential confounding, and observational nature. Genetic association alone does not prove that PCSK9 mutations directly cause hypercholesterolemia; functional studies and replication are needed.
COI Unknown
Could not determine conflict of interest status
No conflict of interest or funding information is present in the provided text; severity cannot be determined.
The provided text is only a scientific abstract/summary and does not include authors, affiliations, funding sources, or conflict of interest disclosures. Therefore, a full COI and bias assessment is not possible.
Key takeaways
- 01
Two mutations in PCSK9 were reported to cause autosomal dominant hypercholesterolemia.
- 02
The abstract does not report how many people were studied, how much cholesterol changed, or any relative or absolute risk numbers.
- 03
The abstract does not provide enough information to calculate absolute risk, such as extra cases per 1,000 people.
- 04
It also does not say how much these mutations raise cholesterol or heart disease risk.
- 05
The absolute risk increase was not reported in this study.
Practical takeaways
If you have a strong family history of very high LDL cholesterol or early heart disease, ask your doctor whether genetic testing for familial hypercholesterolemia might include PCSK9.
The abstract does not provide clinical recommendations, sample size, or effect sizes. This is general awareness, not medical advice.
low confidenceBe aware that inherited high cholesterol can be caused by mutations in at least three genes: LDLR, APOB, and PCSK9.
Based on abstract only; full paper not available; corrections exist and should be checked.
low confidenceWhy this study matters
Beyond LDLR and APOB: A Third Culprit
Autosomal dominant hypercholesterolemia (ADH) was already linked to mutations in LDLR and APOB. This study mapped a third locus, HCHOLA3 at chromosome 1p32, and reported two mutations in PCSK9 that cause ADH. No effect sizes, sample size, or absolute risks were reported in the abstract.
Most people think familial high cholesterol comes from only one or two genes. This discovery adds a third major player, reshaping how we understand inherited cholesterol disorders.
PCSK9 Makes a Liver Protein Called NARC-1
PCSK9 encodes NARC-1 (neural apoptosis regulated convertase), a newly identified human subtilase that is highly expressed in the liver and contributes to cholesterol homeostasis. The abstract does not specify how NARC-1's activity changes cholesterol levels.
The liver is the body's cholesterol control center. A liver-expressed protein that helps regulate cholesterol could be a target for new treatments.
High-Impact Discovery, Sparse Abstract
The abstract reports the key genetic finding but provides no sample size, effect sizes, confidence intervals, or absolute risk data. The paper has been cited 2,983 times and has published corrections/errata, so readers should check correction notices.
A landmark discovery can be described in a short abstract, but missing numbers make it hard to judge how strong the evidence is. It's a lesson in reading science critically.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Scientists found that two tiny changes in a gene called PCSK9 can cause a severe inherited form of high cholesterol called autosomal dominant hypercholesterolemia. This gene makes a protein called NARC-1 that is active in the liver and helps control cholesterol.
Research results
Two mutations in PCSK9 were reported to cause autosomal dominant hypercholesterolemia. The abstract does not report how many people were studied, how much cholesterol changed, or any relative or absolute risk numbers.
What this means - more context
The abstract does not provide enough information to calculate absolute risk, such as extra cases per 1,000 people. It also does not say how much these mutations raise cholesterol or heart disease risk. The absolute risk increase was not reported in this study.
To identify a third genetic locus for autosomal dominant hypercholesterolemia (ADH) after mapping HCHOLA3 to chromosome 1p32, and to test whether mutations in PCSK9 cause ADH.
ADH is a coronary heart disease risk factor characterized by elevated LDL cholesterol and is associated with mutations in LDLR or APOB. The authors mapped HCHOLA3 at 1p32 and report two mutations in PCSK9 that cause ADH. PCSK9 encodes NARC-1, a liver-expressed human subtilase contributing to cholesterol homeostasis. No effect sizes, sample size, or absolute risks are reported in the abstract. This study has published corrections/errata; readers should check the correction notices for updated information.
Methods Used
Abstract states mapping of HCHOLA3 to 1p32 and identification of two PCSK9 mutations causing ADH. Subject recruitment, sample size, control group, sequencing, and statistical methods are not specified in the abstract.
Main Finding
Two specific mutations in the PCSK9 gene cause autosomal dominant hypercholesterolemia. No effect sizes or absolute risk estimates are reported in the abstract.
Confidence Level
Limited - based on abstract only, full methodology not available; no sample size, statistical details, or effect sizes. Corrections/errata exist and should be checked.
Study Flags
Red Flags
- •Full text not available - methodology details cannot be verified
- •Study has corrections/errata; readers should check correction notices for updated information
- •Abstract only; no sample size, effect sizes, confidence intervals, or absolute risk data reported
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Practical Takeaways
If you have a strong family history of very high LDL cholesterol or early heart disease, ask your doctor whether genetic testing for familial hypercholesterolemia might include PCSK9.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 520 / 100
Probability of being correct
Researchers compare people who have a condition (cases) with similar people who do not (controls), looking back in time for differences in exposure. Useful but more prone to bias.
Human Case-Control
Subject
Lower probability
on the GRADE evidence scale
This study found that people with a certain cholesterol problem often have changes in a specific gene. It's like noticing that people with a disease often have a certain feature, but it doesn't prove the feature causes the disease. We can only say they are linked, not that one causes the other.
Strengths
- Identified a novel locus (HCHOLA3) and specific mutations in PCSK9
- Genetic mapping and mutation detection provide biological plausibility
- Findings align with known cholesterol homeostasis pathways
Weaknesses
- Full methodology not available - based on abstract only
- Case-control design cannot establish causation
- Control group details and sample size unknown
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Scientists found that two tiny changes in a gene called PCSK9 can cause a severe inherited form of high cholesterol called autosomal dominant hypercholesterolemia. This gene makes a protein called NARC-1 that is active in the liver and helps control cholesterol.
Research results
Two mutations in PCSK9 were reported to cause autosomal dominant hypercholesterolemia. The abstract does not report how many people were studied, how much cholesterol changed, or any relative or absolute risk numbers.
What this means - more context
The abstract does not provide enough information to calculate absolute risk, such as extra cases per 1,000 people. It also does not say how much these mutations raise cholesterol or heart disease risk. The absolute risk increase was not reported in this study.
To identify a third genetic locus for autosomal dominant hypercholesterolemia (ADH) after mapping HCHOLA3 to chromosome 1p32, and to test whether mutations in PCSK9 cause ADH.
ADH is a coronary heart disease risk factor characterized by elevated LDL cholesterol and is associated with mutations in LDLR or APOB. The authors mapped HCHOLA3 at 1p32 and report two mutations in PCSK9 that cause ADH. PCSK9 encodes NARC-1, a liver-expressed human subtilase contributing to cholesterol homeostasis. No effect sizes, sample size, or absolute risks are reported in the abstract. This study has published corrections/errata; readers should check the correction notices for updated information.
Methods Used
Abstract states mapping of HCHOLA3 to 1p32 and identification of two PCSK9 mutations causing ADH. Subject recruitment, sample size, control group, sequencing, and statistical methods are not specified in the abstract.
Main Finding
Two specific mutations in the PCSK9 gene cause autosomal dominant hypercholesterolemia. No effect sizes or absolute risk estimates are reported in the abstract.
Confidence Level
Limited - based on abstract only, full methodology not available; no sample size, statistical details, or effect sizes. Corrections/errata exist and should be checked.
Study Flags
Red Flags
- •Full text not available - methodology details cannot be verified
- •Study has corrections/errata; readers should check correction notices for updated information
- •Abstract only; no sample size, effect sizes, confidence intervals, or absolute risk data reported
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Practical Takeaways
If you have a strong family history of very high LDL cholesterol or early heart disease, ask your doctor whether genetic testing for familial hypercholesterolemia might include PCSK9.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 520 / 100
Probability of being correct
Researchers compare people who have a condition (cases) with similar people who do not (controls), looking back in time for differences in exposure. Useful but more prone to bias.
Human Case-Control
Subject
Lower probability
on the GRADE evidence scale
This study found that people with a certain cholesterol problem often have changes in a specific gene. It's like noticing that people with a disease often have a certain feature, but it doesn't prove the feature causes the disease. We can only say they are linked, not that one causes the other.
Strengths
- Identified a novel locus (HCHOLA3) and specific mutations in PCSK9
- Genetic mapping and mutation detection provide biological plausibility
- Findings align with known cholesterol homeostasis pathways
Weaknesses
- Full methodology not available - based on abstract only
- Case-control design cannot establish causation
- Control group details and sample size unknown
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
We only have a short summary of the study, not all the details. That makes it hard to know if the study was done well, so we should be careful about trusting the results too much. More research is needed to confirm.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
0 / 100
- Randomizationrandomization unclear
- Blindingblinding unclear
- Control groupno control group
- Sample sizeno sample size reported
- Follow-upno follow-up reported
100 / 100
0 / 100
- P-valuesno p-values reported
- Effect sizeno effect size reported
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 520 / 100
Probability of being correct
Researchers compare people who have a condition (cases) with similar people who do not (controls), looking back in time for differences in exposure. Useful but more prone to bias.
This design cannot establish causation — the findings describe an association, not a cause. Case-control design cannot establish causation due to lack of randomization, potential confounding, and observational nature. Genetic association alone does not prove that PCSK9 mutations directly cause hypercholesterolemia; functional studies and replication are needed.
COI Unknown
Could not determine conflict of interest status
No conflict of interest or funding information is present in the provided text; severity cannot be determined.
The provided text is only a scientific abstract/summary and does not include authors, affiliations, funding sources, or conflict of interest disclosures. Therefore, a full COI and bias assessment is not possible.
Standing
Who’s using this study?
The videos and claims on this site that lean on this study, and the researchers who wrote it.
1 video from Dr Brad Stanfield cite this study, drawing 0 claims from it.
No specific claims extracted from this video yet.
Authored by
26 researchersIf this is your work, this is how we attribute it on Fit Body Science. Marianne Abifadel is listed as the lead author.